Teva Pharma (TEVA) Naming Permanent CEO is Credit Positive - Moody's

Moody's Investors Service commented on Teva Pharmaceutical Industries Ltd.'s (NYSE: TEVA) announcement that Erez Vigodman will become President and CEO effective February 11, 2014. The selection of Vigodman -- who has been on Teva's board of directors since 2009 -- is credit positive as it reduces the risk that there will be a significant departure from Teva's previously-stated strategy. There is no change to Teva's A3 rating or the negative outlook.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Oppenheimer Starts Teva Pharma (TEVA) at Outperform
• McGee Air Services names Ben Reed as president effective Oct. 1
• Core Scientific names Jay Elms as chief commercial officer